Fire breaks out on ship carrying EVS
An American shipping company has banned electric vehicles from travelling on its vessels following a series of fires at sea.
The latest fire saw the Morning Midas car carrier burn at sea for three weeks with more than 3000 cars on board before capsizing and sinking to a depth of more than 16,000 feet near Alaska.
In this photo provided by the U.S. Coast Guard, smoke rises from cargo vessel Morning Midas, a cargo ship carrying around 3000 vehicles to Mexico. Picture: U.S. Coast Guard/Courtesy Air Station Kodiak via AP
MORE: Burnt through – pics reveal EV inferno
It follows similar incidents for car carriers such as the Fremantle Highway in 2023 and Felicity Ace in 2022.
All three ships were carrying a mix of electric, hybrid, and conventionally powered vehicles.
Matson, a company that specialises in shipping goods including vehicles between the US mainland, Hawaii, Guam and Alaska, surprised customers in July by declaring an EV ban.
The merchant ship Felicity Ace adrift after a fire broke out on board in 2022 off the Portuguese coast. Photo: Portuguese Navy / AFP
MORE: Ship carrying EVs sinks in the pacific
A statement issued by the company said that 'due to increasing concern for the safety of transporting vehicles powered by large lithium-ion batteries, Matson is suspending acceptance of used or new electric vehicles (EVs) and plug-in hybrid vehicles for transport aboard its vessels,' it said.
'Effective immediately, we have ceased accepting new bookings for these shipments to/from all trades.'
The company says it 'continues to support industry efforts to develop comprehensive standards and procedures to address fire risk posed by lithium-ion batteries at sea and plans to resume acceptance of them when appropriate safety solutions that meet our requirements can be implemented.'
Salvage workers recover an electric Mercedes from the fire-stricken Fremantle Highway ship. YouTube/Eemskrant
MORE: Ship packed with luxury cars sunk
The shipping industry is scrambling to address the risk of EV fires.
A Maritime Technologies Forum report published in March 2025 states that although some regional guidelines are in place, 'there are no international regulations dedicated for safe carriage of EVs'.
The American Bureau of Shipping (ABS) says 'batteries that power electric vehicles pose unique fire risks, particularly thermal runaway … Lithium-ion battery fires can be difficult to extinguish, burn at extremely high temperatures, generate flammable and toxic gases, and may reignite even after being seemingly controlled'.
A fire broke out on the Fremantle Highway late on July 25, 2023, killing one crew member, and prompting a massive effort to extinguish the flames. Photo: Handout / Netherlands Coastguards / AFP
Christopher Wiernicki, chairman and chief executive of the ABS, says 'runaway electric vehicle fires can reach temperatures of 1,200°F (650°C) or higher and present unprecedented safety challenges to the shipping industry, which connects manufactured vehicles to global markets'.
He says the ABS recently developed a software model for EV fires that 'will be a foundation of the ultimate solution' for rules surrounding the shipping of electric vehicles.
Originally published as Fire breaks out on ship carrying EVS
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
News.com.au
43 minutes ago
- News.com.au
Health Check: Cancer drug developers drive further positive Car-T results
Imugene and Chimeric have unveiled further promising results for their Car-T immune-oncology assets Rhythm Biosciences shares soar 18% on kit validation results While investors are picky, equity dollars continue to flow There's a long drive ahead, but Imugene (ASX:IMU) and Chimeric Therapeutics (ASX:CHM) are heading in the right direction with their Car-T therapies that trick up the body's T-cells to be better cancer fighters. Imugene shares this morning leaped 10%, after the company reported two additional 'partial responses' in its phase 1b trial. The study aims to combat relapsed diffuse large B-cell lymphoma (DLBCL), an aggressive blood cancer. Imugene's Car-T therapy, azer-cel, could result in the first 'off the shelf' Car-T treatment derived from donor cells (rather than the patient). The trial tally now stands at six 'complete responses' and five partial responses. A complete response is disappearance of signs of cancer – tentatively known as a cure. A partial response is a cancer reduction of at least 50%. In all, the trial has achieved an overall response rate of 79%. On July 14 Imugene said nine out of 12 patients had responded, prompting a circa $37 million capital raising. The first patients dosed (last year) remain cancer free at 15 months. They had not responded to several therapy attempts. The trial is underway at ten US sites and six local sites, including Sydney's Royal Prince Alfred Hospital. Cells are 'hard at work' Chimeric reports 'encouraging early results' after moving to a stronger dose in its phase I/II study. The trial tests the company's Car-T candidate CHM CDH17. Chimeric reports one patient with stable disease and "anti-tumour activity", with the lesion shrinking by 12%. The boffins define stable disease as no change in tumour size, or up to 30% shrinkage. One patient from the first dose cohort remains with stable disease eight months after dosing, with an 18% shrinkage. 'This is great progress,' says Chimeric CEO Dr Rebecca McQualter. 'We can see the cells are hard at work to more data'. The trial has enrolled patients with advanced colorectal cancer, gastric cancer and intestinal neuroendocrine tumours. CHM CDH17 targets CDH17, a cancer biomarker 'associated with poor prognosis and metastases in the most common gastrointestinal tumours'. Chimeric expects to enrol 15 patients in the phase I part of the study, with an expanded cohort for phase II. Rhythm's test validation is in the groove Rhythm Biosciences (ASX:RHY) shares today surged a sector-leading ing 18%, on further validation results of the company's Colostat bowel cancer assay. Having received its first kits from the manufacturer for final internal testing, the company tested them on new blood samples from patients with no bowel cancer at any of the stages (one to four). 'This study was critical as the initial intended use of Colostat is for symptomatic patients who could well have early and late-stage disease,' the company says. While Rhythm will complete further studies, the data on 300 patient samples shows that Colostat is equally effective at detecting bowel cancer across all stages. Rhythm will apply to the local National Association of Testing Authorities to have Colostat approved under the common-used laboratory-developed route. Lung imager breathes easier with deep-pocketed backer Friday's keen investor response to lung imager 4D Medical's 4D Medical's (ASX:4DX) funding arrangement with ProMedicus (ASX:PME) no doubt has to do with the mere 'vibe' of the latter taking an interest in the market minnow. In its first tie up with a listed peer, the $30 billion market cap Pro Medicus has extended a $10 million 'hybrid debt and equity loan' to 4D Medical. The duo don't compete with each other. 4D Medical will use the funds to develop its product pipeline and advance a US Food and Drug Administration (FDA) marketing application. This is for the company's ventilation perfusion product, for use in computed tomography. The loan attracts 12.5% interest and is repayable in cash and 'shares valued at the same amount as the cash repayment'. The deal is non-dilutive if the share price remains where is it, with 'upside alignment' for both parties if they perform strongly over the next two years. 4D also reported customer receipts of $1.61 million for the June quarter, up 19%, taking full-year receipts to $12 months to $5.38 million (up 87%). The company undertook 74,000 scans for the quarter, up 105% year on year. 4D had outflows of $9.47 million, down 16% compared with the March quarter. The company ended June with cash of $9.9 million, with a $6 million R&D tax refund due 'in coming weeks'. 4D Medical shares surged 30% on Friday and edged up a further 10% today. Spare us a dime? Other life companies are bringing in the dollars via traditional equity means. The developer of a non-radiation-based imaging for breast and other cancers, Imagion Biosystems (ASX:IBX) has raised $3.5 million in a two-tranche institutional placement. The price was 1.5 cents per share, a 10% discount. The funds will support Imagion's proposed phase II US trial for Her-2 breast cancers. Nyrada (ASX:NYR) has raised $8.25 million via a placement. The company is developing Xolatryp, which blocks a certain ion channel to protect key cells in vital organs when under stress. This could be after a blood clot or reperfusion (the sudden flow of blood returning to an organ or tissue). Nyrada is preparing for a phase IIa acute myocardial infarction trial and has nearly finished a phase I cardioprotection study. Kiwi diagnostics house Pacific Edge (ASX:PEB) has raised NZ$20.7 million in a placement and share purchase plan, having targeted NZ$20 million. US authorities recently cancelled reimbursement of the Pacific Edge's bladder cancer test Cxbladder, but the company is challenging the decision. Finally, foetal monitoring house HeraMED (ASX:HMD) has raised $1.98 million 1.2 cents a share, a 4.8% discount. Reporting latecomers: please wait to be seated Companies needed to lodge their quarterly reports within a month. But the ASX 'ushers' will still see them to their seats if they're not too late. The bourse on Friday suspended Syntara (ASX:SNT) for non-lodgment – but not for long. The myelofibrosis drug developer was allowed to resume trading, having lodged before the opening of Friday's trading. The quarterlies were due on Thursday. Syntara reported receipts of $78,000, cash outflow of $3.7 million and a $15 million cash balance. By the end of September, investors should expect final results from the company's phase II program that evaluated its drug candidate amsulostat, in 16 patients. An interim readout showed eight of 11 evaluable patients (73%) achieved a reduction of 50% or more in their myelofibrosis symptoms. Syntara awaits an FDA review of its application to start a follow-on phase II/III trial. Meanwhile, Syntara will seek shareholder approval to grant 4.769 million of incentive shares to CEO Gary Phillips, at nil consderation.
Perth Now
an hour ago
- Perth Now
Asia shares sideswiped by US economic jitters
Asian share markets have followed Wall Street lower as fears for the US economy returned with a vengeance, spurring investors to price in an almost certain rate cut for September and undermining the dollar. Some early resilience in US stock futures and a continued retreat in oil prices did help limit the losses, but the bleak message from the July payrolls report was hard to ignore. Not only had revisions meant payrolls were 290,000 below where investors had thought they would be, but the three-month average slowed to just 35,000 from 231,000 at the start of the year. "The report brings payroll growth closer in line with big data indicators of job gains and the broader growth dataset, both of which have slowed significantly in recent months," noted analysts at Goldman Sachs. "Taken together, the economic data confirm our view that the US economy is growing at a below-potential pace." Neither did the reaction of President Donald Trump instil confidence, as the firing of the head of Labor Statistics threatened to undermine confidence in US economic data. Likewise, news that Trump would get to fill a governorship position at the Federal Reserve early added to worries about the politicisation of interest rate policy. Analysts assume the appointee will be loyal to Trump alone, though the president did grudgingly concede that Fed Chair Jerome Powell would likely see out his term. "It opens the prospect of broader support on the Fed Board for lower rates sooner rather than later," said Ray Attrill, head of FX research at NAB. "Fed credibility, and the veracity of the statistics on which they base their policy decisions, are both now under the spotlight." Markets moved quickly to price in a lot more easing with the probability of a September rate cut swinging to 90 per cent, from 40 per cent before the jobs report. Futures extended the rally on Monday to imply 65 basis points of easing by year-end, compared to 33 basis points pre-data. Markets have essentially already eased for the Fed with two-year Treasury yields down another 4 basis points at 3.661 per cent. They tumbled almost 25 basis points on Friday in the biggest one-day drop since August last year. The prospect of lower borrowing costs offered some support for equities and S&P 500 futures inched up 0.1 per cent, while Nasdaq futures rose 0.2 per cent. Asian share markets, however, were still catching up with Friday's retreat and the 225-stock Nikkei fell 2.1 per cent, while South Korea dipped 0.2 per cent. MSCI's broadest index of Asia-Pacific shares outside Japan broke the mould and firmed 0.3 per cent. Wall Street has also taken comfort in an upbeat results season. Around two-thirds of the S&P 500 have reported and 63 per cent have beaten forecasts. Earnings growth is estimated at 9.8 per cent, up from 5.8 per cent at the start of July. Companies reporting this week include Disney, McDonald's, Caterpillar and some of the large pharmaceutical groups. The dismal US jobs data did put a dent in the dollar's crown of exceptionalism, snuffing out what had been a promising rally for the currency. The dollar dipped 0.1 per cent to 147.24 yen, having shed an eye-watering 2.3 per cent on Friday, while the euro stood at $1.1585 after bouncing 1.5 per cent on Friday. The dollar index was pinned at 98.659, having been toppled from last week's top of 100.250. Sterling was more restrained at $1.3287 as markets are 87 per cent priced for the Bank of England to cut rates by a quarter point at a meeting on Thursday. The BoE board itself is expected to remain split on easing, while markets still favour two further cuts by the middle of next year. In commodity markets, gold was flat at $US3361 ($A5,189) an ounce, having climbed more than two per cent on Friday. Oil prices extended their latest slide as OPEC+ agreed to another large rise in output for September, which completely reverses last year's cuts of 2.2 million barrels per day. Brent dropped 0.6 per cent to $US69.24 ($A106.89) a barrel, while US crude also fell 0.6 per cent to $US66.93 ($A103.33) per barrel. (Reporting by Wayne Cole; Editing by Jacqueline Wong)
News.com.au
2 hours ago
- News.com.au
AI search pushing an already weakened media ecosystem to the brink
Generative artificial intelligence assistants like ChatGPT are cutting into traditional online search traffic, depriving news sites of visitors and impacting the advertising revenue they desperately need, in a crushing blow to an industry already fighting for survival. "The next three or four years will be incredibly challenging for publishers everywhere. No one is immune from the AI summaries storm gathering on the horizon," warned Matt Karolian, vice president of research and development at Boston Globe Media. "Publishers need to build their own shelters or risk being swept away." While data remains limited, a recent Pew Research Center study reveals that AI-generated summaries now appearing regularly in Google searches discourage users from clicking through to source articles. When AI summaries are present, users click on suggested links half as often compared to traditional searches. This represents a devastating loss of visitors for online media sites that depend on traffic for both advertising revenue and subscription conversions. According to Northeastern University professor John Wihbey, these trends "will accelerate, and pretty soon we will have an entirely different web." The dominance of tech giants like Google and Meta had already slashed online media advertising revenue, forcing publishers to pivot toward paid subscriptions. But Wihbey noted that subscriptions also depend on traffic, and paying subscribers alone aren't sufficient to support major media organizations. - Limited lifelines - The Boston Globe group has begun seeing subscribers sign up through ChatGPT, offering a new touchpoint with potential readers, Karolian said. However, "these remain incredibly modest compared to other platforms, including even smaller search engines." Other AI-powered tools like Perplexity are generating even fewer new subscriptions, he added. To survive what many see as an inevitable shift, media companies are increasingly adopting GEO (Generative Engine Optimization) -- a technique that replaces traditional SEO (Search Engine Optimization). This involves providing AI models with clearly labeled content, good structure, comprehensible text, and strong presence on social networks and forums like Reddit that get crawled by AI companies. But a fundamental question remains: "Should you allow OpenAI crawlers to basically crawl your website and your content?" asks Thomas Peham, CEO of optimization startup OtterlyAI. Burned by aggressive data collection from major AI companies, many news publishers have chosen to fight back by blocking AI crawlers from accessing their content. "We just need to ensure that companies using our content are paying fair market value," argued Danielle Coffey, who heads the News/Media Alliance trade organization. Some progress has been made on this front. Licensing agreements have emerged between major players, such as the New York Times and Amazon, Google and Associated Press, and Mistral and Agence France-Presse, among others. But the issue is far from resolved, as several major legal battles are underway, most notably the New York Times' blockbuster lawsuit against OpenAI and Microsoft. - Let them crawl - Publishers face a dilemma: blocking AI crawlers protects their content but reduces exposure to potential new readers. Faced with this challenge, "media leaders are increasingly choosing to reopen access," Peham observed. Yet even with open access, success isn't guaranteed. According to OtterlyAI data, media outlets represent just 29 percent of citations offered by ChatGPT, trailing corporate websites at 36 percent. And while Google search has traditionally privileged sources recognized as reliable, "we don't see this with ChatGPT," Peham noted. The stakes extend beyond business models. According to the Reuters Institute's 2025 Digital News Report, about 15 percent of people under 25 now use generative AI to get their news. Given ongoing questions about AI sourcing and reliability, this trend risks confusing readers about information origins and credibility -- much like social media did before it. "At some point, someone has to do the reporting," Karolian said. "Without original journalism, none of these AI platforms would have anything to summarize." Perhaps with this in mind, Google is already developing partnerships with news organizations to feed its generative AI features, suggesting potential paths forward. "I think the platforms will realize how much they need the press," predicted Wihbey -- though whether that realization comes soon enough to save struggling newsrooms remains an open question. tu/arp/jgc
